Literature DB >> 22075854

Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease.

Anna K Trauernicht1, Steven J Steiner.   

Abstract

BACKGROUND: Serum antibodies, including ASCA, anti-OmpC, and ANCA, correlate with disease location and predict disease phenotype in inflammatory bowel disease. AIM: The objective of this study was to determine relationships between serum antibody status and anthropometric data for children with newly diagnosed Crohn's disease.
METHODS: A retrospective review was conducted on children diagnosed with Crohn's disease at our institution from 2003 to 2008. Patients who had ASCA IgA, ASCA IgG, anti-OmpC, and pANCA antibodies, and anthropometric data measured before diagnosis and therapy were included. Z-scores for height and weight were compared among groups according to the presence of specific antibodies. Spearman's rank correlation was used to assess association between antibodies and growth data.
RESULTS: One hundred and two patients, mean age 11.9 years, met the inclusion criteria. Patients with the presence of any of the four antibodies had lower mean height and weight z-scores than patients without any antibodies present. When individual antibodies were studied, patients with positive ASCA titers had lower mean weight and height z-scores than patients without any antibodies present. Spearman's rank correlation coefficient demonstrated a significant association between increasing ASCA titers and lower weight z-scores, but not lower height z-scores.
CONCLUSIONS: Pediatric patients with newly diagnosed Crohn's disease and the presence of ASCA antibodies have lower mean height and weight z-scores. This study provides evidence that specific subsets of children with Crohn's disease may be at greater risk of growth impairment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075854     DOI: 10.1007/s10620-011-1954-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Authors:  E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

2.  Growth and clinical course of children with Crohn's disease.

Authors:  A M Griffiths; P Nguyen; C Smith; J H MacMillan; P M Sherman
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

Review 3.  Fundamental mechanisms of growth failure in inflammatory bowel disease.

Authors:  Anne Ballinger
Journal:  Horm Res       Date:  2002

4.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

5.  Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Authors:  Marla C Dubinsky; Ying-Chao Lin; Debra Dutridge; Yoana Picornell; Carol J Landers; Sharmayne Farrior; Iwona Wrobel; Antonio Quiros; Eric A Vasiliauskas; Bruce Grill; David Israel; Ron Bahar; Dennis Christie; Ghassan Wahbeh; Gary Silber; Saied Dallazadeh; Praful Shah; Danny Thomas; Drew Kelts; Robert M Hershberg; Charles O Elson; Stephan R Targan; Kent D Taylor; Jerome I Rotter; Huiying Yang
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

6.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease.

Authors:  Suzanne Lesage; Habib Zouali; Jean-Pierre Cézard; Jean-Frédéric Colombel; Jacques Belaiche; Sven Almer; Curt Tysk; Colm O'Morain; Miquel Gassull; Vibeke Binder; Yigael Finkel; Robert Modigliani; Corinne Gower-Rousseau; Jeanne Macry; Françoise Merlin; Mathias Chamaillard; Anne-Sophie Jannot; Gilles Thomas; Jean-Pierre Hugot
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

7.  Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.

Authors:  Marian Pfefferkorn; Georgine Burke; Anne Griffiths; James Markowitz; Joel Rosh; David Mack; Anthony Otley; Subra Kugathasan; Jonathan Evans; Athos Bousvaros; M Susan Moyer; Robert Wyllie; Maria Oliva-Hemker; Ryan Carvalho; Wallace Crandall; David Keljo; T D Walters; Neal LeLeiko; Jeffrey Hyams
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-02       Impact factor: 2.839

8.  Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.

Authors:  D G Forcione; M J Rosen; J B Kisiel; B E Sands
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease.

Authors:  M E Kanof; A M Lake; T M Bayless
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

10.  Presenting features of inflammatory bowel disease in Great Britain and Ireland.

Authors:  A Sawczenko; B K Sandhu
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

View more
  1 in total

Review 1.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.